Philadelphia, PA, USA, December 9, 2025, First Patient Enrolled in GOG-3133/ FRAmework-01 Phase 3 Study Evaluating Sofetabart ...

In atopic dermatitis, the first interleukin-22 inhibitor to reach late clinical trials is showing uncommonly broad suppression of biomarkers associated with disease activity.

Discover why CLLS is a top speculative Buy, with promising CAR-T therapies, strong big pharma partnerships, and attractive ...

A new vaccine targeting triple-negative breast cancer (TNBC) has shown promising results in its first human clinical trial.

Roche (RHHBY) posts Phase 3 trial data for breast cancer drug giredestrant, boosting the shares of Olema (OLMA) which is advancing a similar drug. Read more here.

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the first patient enrollment for its phase ...

An experimental vaccine targeting aggressive triple-negative breast cancer (TNBC) has shown encouraging early results in ...

As previously announced, Medicenna will present updated clinical data from the ABILITY-1 Phase 1/2 Study, evaluating MDNA11 as a monotherapy and in combination with pembrolizumab, on December 10 th at ...

Short bursts of high fructose intake made key immune cells in healthy adults more sensitive to bacterial toxins and more ...

MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS ...

This study provides useful insights into addressing the question of whether the prevalence of autoimmune disease could be driven by sex differences in the T cell receptor (TCR) repertoire, correlating ...

Triple-negative breast cancer (TNBC) is widely regarded as one of the most aggressive and difficult, often deadly, forms of breast cancer. Unlike other subtypes, TNBC lacks oestrogen receptors (ER), ...